Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the data from its oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.
KRAKOW, Poland, March 8, 2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the data from its oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, U.S. Posters to be presented at the conference will include data from RVU120, a CDK8/CDK19 inhibitor program targeting hematologic and solid tumors, and data from an MTA-cooperative PRMT5 inhibitor program. “We are excited to share the recent preclinical data in breast cancer from our most advanced oncology program, RVU120. This selective inhibitor of CDK8/CDK19 is currently in Phase 1b clinical development for the treatment of acute myeloid leukemia or high-risk myelodysplastic syndromes, as well as in patients with metastatic or advanced solid tumors, and has already delivered promising data,” said Krzysztof Brzózka, Chief Scientific Officer at Ryvu Therapeutics. “We have also made rapid progress in our MTA-cooperative PRMT5 inhibitor program, and we look forward to sharing these updates with the scientific community,” adds Dr. Brzózka. Abstract/Poster Details: Title: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo Title: Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers Title: Trials in Progress – RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors About AACR Annual Meeting The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention, to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. Additional information is available on the AACR conference website http://www.aacr.org. About Ryvu Therapeutics Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are: RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors and SEL24 (MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia. The Company was founded in 2007, and is headquartered in Krakow, Poland. Ryvu is listed on the main market of the Warsaw Stock Exchange, and is a component of sWIG80 index. For more information, please see www.ryvu.com.
SOURCE Ryvu Therapeutics | ||
Company Codes: Warsaw:RVU, Frankfurt:9Y4, LSE:0RKT |